Perimeter Medical's Claire OCT+AI Receives FDA Approval for Breast Cancer Surgery Margin Assessment

Key Takeaways

• Claire OCT+AI becomes the first FDA-approved AI-enabled device for intraoperative breast cancer margin assessment
• The technology helps surgeons evaluate tissue margins in real-time during breast cancer surgery to reduce re-operation rates
• Perimeter Medical will showcase the device at the American Society of Breast Surgeons meeting April 29-May 3, 2026

---

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) announced the formal unveiling of its groundbreaking Claire™ OCT+AI system at the 27th Annual Meeting of the American Society of Breast Surgeons (ASBrS) in Seattle, Washington, from April 29 to May 3, 2026.

Historic FDA Approval

Claire received U.S. Food and Drug Administration (FDA) premarket approval (PMA) in March 2026, marking a significant milestone as the first AI-enabled imaging device specifically designed for intraoperative breast cancer margin assessment. This approval represents a major advancement in surgical oncology technology.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Revolutionary Technology for Breast Cancer Surgery

The Claire OCT+AI system combines optical coherence tomography (OCT) with artificial intelligence to provide real-time tissue analysis during breast cancer surgery. This technology enables surgeons to immediately assess whether cancer cells remain at the edges of removed tissue, potentially reducing the need for additional surgeries.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Clinical Significance

Approximately 20-30% of breast cancer patients require re-operation due to positive margins discovered during post-surgical pathology. Claire’s real-time assessment capability could significantly reduce these re-operation rates, improving patient outcomes while reducing healthcare costs and emotional burden on patients.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Company Positioning

Toronto and Dallas-based Perimeter Medical is a commercial-stage medical technology company focused on advanced imaging solutions for cancer surgery. The Claire system positions the company at the forefront of AI-driven surgical technology, potentially capturing significant market share in the growing surgical imaging market.

The ASBrS presentation will provide surgeons and healthcare professionals their first comprehensive look at this FDA-approved technology, marking the beginning of commercial availability for this innovative surgical tool.

---

Frequently Asked Questions

What does Claire OCT+AI mean for breast cancer patients?

Claire helps surgeons determine in real-time during surgery whether all cancer cells have been removed, potentially reducing the need for additional surgeries that currently affect 20-30% of breast cancer patients.

When will Claire OCT+AI be available in hospitals?

With FDA approval received in March 2026 and the formal unveiling at ASBrS in April 2026, Perimeter Medical is expected to begin commercial deployment to hospitals and surgical centers soon.

How does Claire compare to current margin assessment methods?

Unlike traditional methods that require waiting days for pathology results, Claire provides immediate AI-powered analysis during surgery, allowing surgeons to make real-time decisions about tissue removal.

Related coverage

• Breast Cancer Statistics Worldwide: What the Data Shows
• Vabysmo gains EU approval for retinal vein occlusion: what changes next
• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial